-
Abbott Laboratories v. Sandoz, Inc. DC
- 1:05-cv-05373
- N.D. Ill.
- Judge: Richard A. Posner +2
- Filed: 09/16/2005
- Closed: 06/24/2010
- Latest Docket Entry: 07/15/2010
- PACER
- Docket updated daily
2
Plaintiffs
1
Defendant
1
Accused
Product
3
Patents-in-Suit
1,743
Days in
Litigation
-
Abbott Laboratories v. Sandoz, Inc. DC
- 1:05-cv-05373
- N.D. Ill.
- Judge: Richard A. Posner +2
- Filed: 09/16/2005
- Closed: 06/24/2010
- Latest Docket Entry: 07/15/2010
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Previously Presiding
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition for extended release of clarithromycin in the gastrointestinal tract, to be administered orally, comprising clarithromycin, which, when administered once a day, induces a statistically significantly lower degree of
view more
|
Invalid
Entry 215 |
2 |
The pharmaceutical composition of claim 1, wherein the composition when administered to a patient has improved taste perversion compared to an immediate release formulation containing clarithromycin.
|
Invalid
Entry 215 |
3 |
The pharmaceutical composition of claim 1, wherein the composition when administered to a patient has reduced severity of gastrointestinal adverse side effects.
|
Invalid
Entry 215 |
4 |
The pharmaceutical composition of claim 1, further providing a 3-4 fold reduction in incidence rates for taste perversion as compared to the immediate release formulation containing clarithromycin when administered to a group of patients.
|
Invalid
Entry 215 |
8 |
A pharmaceutical composition for extended release of clarithromycin in the gastrointestinal tract, to be administered orally, comprising clarithromycin, which, when administered once a day, induces a statistically significantly lower degree of
view more
|
Invalid
Entry 215 |
9 |
The pharmaceutical composition of claim 8, wherein the composition when administered to a patient has improved taste perversion compared to an immediate release formulation containing clarithromycin.
|
Invalid
Entry 215 |
10 |
The pharmaceutical composition of claim 8, wherein the composition when administered to a patient has reduced severity of gastrointestinal adverse side effects.
|
Invalid
Entry 215 |
11 |
The pharmaceutical composition of claim 8, further providing a 3-4 fold reduction in incidence rates for taste perversion as compared to the immediate release formulation containing clarithromycin when administered to a group of patients.
|
Invalid
Entry 215 |
15 |
The pharmaceutical composition of claim 1, wherein, the C<sub>max </sub>is 2.45±0.69 μg/ml, the C<sub>min </sub>is 0.70±0.37 μg/ml, the T<sub>max </sub>is 8.6±4.4 hours, the AUC<sub>0-24 </sub>is 39.6±12.8 μg·h/mL, and the fluctuation index is
view more
|
Invalid
Entry 215 |
16 |
The pharmaceutical composition of claim 8, wherein the C<sub>max </sub>is 2.66±0.87 μg/ml, the C<sub>min </sub>is 0.67±0.39 μg/ml, the T<sub>max </sub>is 6.9±3.3 hours, the AUC<sub>0-24 </sub>is 40.2±13.8 μg·h/mL, and the fluctuation index is
view more
|
Invalid
Entry 215 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment, comprising an erythromycin derivative and from about 5 to about 50% by weight of a pharmaceutically acceptable polymer, so that
view more
|
Enforceable and Valid (102 and 103)
Entry 454 |
2 |
The pharmaceutical composition of claim 1, wherein the polymer is a hydrophilic water-soluble polymer.
|
Enforceable and Valid (102 and 103)
Entry 454 |
4 |
A pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment, comprising an erythromycin derivative and from about 5 to about 50% by weight of a pharmaceutically acceptable polymer, so that
view more
|
Enforceable and Valid (102 and 103)
Entry 454 |
-
Infringement
Sandoz Inc.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic clarithromycin | US 6,010,718 A | All Asserted Claims |
No infringement
Entry 215
|
Generic clarithromycin | US 6,551,616 B1 | All Asserted Claims |
No infringement
Entry 215
|
Generic clarithromycin | US 6,872,407 B2 | All Asserted Claims |
No infringement
Entry 215
|